The tumor-suppressive role of ALK4/ACVR1B in pancreatic tumorigenesis
ALK4/ACVR1B 在胰腺肿瘤发生中的抑癌作用
基本信息
- 批准号:7531578
- 负责人:
- 金额:$ 21.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-07-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:ActivinsAdenocarcinomaAffectAnimal ModelBeliefBiologicalBiologyBreedingCancer EtiologyCancer ModelCancer PatientCarcinomaCessation of lifeComplexCountryCystic NeoplasmDataDesigner DrugsDetectionDevelopmentDiseaseDisseminated Malignant NeoplasmEarly DiagnosisEmbryoFundingGenesGeneticGenetic EngineeringGenotypeGrantHumanHuman BiologyHuman DevelopmentIntraductal Papillary Breast CarcinomaInvasiveKnock-outKnockout MiceLeadLesionMalignant NeoplasmsMalignant neoplasm of pancreasMarker DiscoveryMediator of activation proteinModelingMucinous NeoplasmMusMutationOncogenesPancreasPancreatic Ductal AdenocarcinomaPancreatic Intraepithelial NeoplasiaPapillaryPathway interactionsPatientsProgress Review GroupPublishingReportingResearch PriorityRoleSamplingSignal PathwaySimulateSpecimenTumor MarkersTumor SuppressionTumor Suppressor GenesType I Activin ReceptorsUncertaintybasebone morphogenetic protein receptorscancer preventioncancer typeductal breast carcinomain vivoinsightmouse modelneoplasticoutcome forecastpancreatic tumorigenesisreceptortooltumortumor progressiontumorigenesis
项目摘要
Pancreatic cancer is the fifth leading cause of cancer death in this country and it is almost
uniformly fatal. The poor prognosis of pancreatic cancer patients can be attributed to the lack of early
detections and effective treatments. Genetic engineered mice have been effective tools for cancer
modeling and pathway studies. A genetic engineered mouse model that simulate a cancer type can be
utilized for tumor marker discovery and contribute to the development of early detections. It can also
further our understanding of a particular signaling pathway that is important for pancreatic
tumorigenesis and lead to the development of designer drugs that are pathway-specific. Here we
propose to study activin signaling pathway in genetic engineered mice, because we have previously
shown that activin signaling pathway is important for human pancreatic tumorigenesis and this
pathway and its funiton in tumor-suppression have not been investigated in vivo.
The TGFa receptor superfamily (TGFa, activin, and BMP receptors) and their mediators are
critical to pancreatic development and tumorigenesis. We have shown previously that activin type I
receptor B (ALK4/ACVR1B) is a tumor-suppressor gene that is biallelically inactivated in pancreatic
ductal adenocarcinoma. However, its function in pancreatic tumorigenesis is largely unknown. The
objective of this proposal is to investigate the tumor-suppressive function of ALK4/ACVR1B in
pancreatic tumorigenesis in Alk4 conditional knock-out mouse models because conventional knockout
mice at the Alk4 gene locus are embryonic lethal. We will also investigate the intrinsic
relationship between Alk4 and Smad4 in tumor suppression in a compound knock-out mouse model.
In addition, we would like to explore the possible role of ALK4/ACVR1B in a subset of pancreatic early
lesions called intraductal papillary mucinous neoplasm (IPMN), which is distinct from pancreatic
ductal adenocarcinoma and its early lesions (pancreatic intraepithelial neoplasia, PanIN). The
involvement of ALK4/ACVR1B has not been evaluated in IPMN previously.
It is our belief that to understand the biology of the cancer genes that contribute to the
development of human pancreatic cancer will help us develop better detection and treatment options.
The urgency to detect and treat this deadly disease has prompted the NCI to issue a Progress Review
Group report, in which the NCI identifies the development of ?gene-based model systms that
faithfully parallel the complex biology of human pancreatic cancer? as one of its research priorities
(http://planning.cancer.gov/pdfprgreports/2001pancreatic.pdf). Gene-based animal models that
recapitulate human pancreatic cancer will become avaialbe if this proposal is funded. This grant is
100% relevant to pancreatic cancer.
胰腺癌是这个国家第五大癌症死亡原因,它几乎是
都是致命的。胰腺癌患者预后不良可归因于缺乏早期治疗。
检测和有效的治疗。基因工程小鼠已成为治疗癌症的有效工具
建模和路径研究。一种模拟癌症类型的基因工程小鼠模型可以
用于发现肿瘤标记物,并有助于早期检测的发展。它还可以
进一步了解对胰腺非常重要的特定信号通路
肿瘤的发生和导致针对特定途径的设计药物的开发。在这里我们
建议研究基因工程小鼠的激活素信号通路,因为我们之前已经
激活素信号通路在人胰腺肿瘤发生中起重要作用
其途径及其在肿瘤抑制中的作用尚未在体内进行研究。
TGFa受体超家族(TGFa、激活素和BMP受体)及其介体是
对胰腺发育和肿瘤发生至关重要。我们之前已经证明了激活素I型
B受体(ALK4/ACVR1B)是一种在胰腺中双等位失活的肿瘤抑制基因
导管腺癌。然而,它在胰腺肿瘤发生中的作用在很大程度上还不清楚。这个
本研究的目的是探讨ALK4/ACVR1B对小鼠肿瘤的抑制作用。
Alk4条件性基因敲除小鼠模型胰腺肿瘤的发生
Alk4基因座上的小鼠对胚胎是致命的。我们还将研究内在的
Alk4和Smad4在复合基因敲除小鼠肿瘤抑制中的关系。
此外,我们还想探讨ALK4/ACVR1B在早期胰腺癌中的可能作用。
称为导管内乳头状粘液性肿瘤(IPMN)的病变,与胰腺不同
导管腺癌及其早期病变(胰腺上皮内瘤变,Panin)。这个
ALK4/ACVR1B的参与以前没有在IPMN中被评估过。
我们认为,要了解癌症基因的生物学特性,
人类胰腺癌的发展将帮助我们开发更好的检测和治疗方案。
发现和治疗这种致命疾病的紧迫性促使NCI发布了一份进度回顾
小组报告,其中NCI确定了基于基因的模型系统的发展
忠实地与人类胰腺癌的复杂生物学相比较?作为其研究重点之一
(http://planning.cancer.gov/pdfprgreports/2001pancreatic.pdf).基于基因的动物模型
如果这项提案得到资助,概括性的人类胰腺癌将成为可能。这笔赠款是
100%与胰腺癌相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gloria Huei-Ting Su其他文献
Gloria Huei-Ting Su的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gloria Huei-Ting Su', 18)}}的其他基金
The role of wild-type KRAS in the context of tumor profession and metastasis
野生型 KRAS 在肿瘤发生和转移中的作用
- 批准号:
9047247 - 财政年份:2015
- 资助金额:
$ 21.74万 - 项目类别:
The tumor-suppressive role of ALK4/ACVR1B in pancreatic tumorigenesis
ALK4/ACVR1B 在胰腺肿瘤发生中的抑癌作用
- 批准号:
7640642 - 财政年份:2008
- 资助金额:
$ 21.74万 - 项目类别:
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
人胰腺导管腺癌小鼠模型
- 批准号:
6811716 - 财政年份:2004
- 资助金额:
$ 21.74万 - 项目类别:
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
人胰腺导管腺癌小鼠模型
- 批准号:
7254163 - 财政年份:2004
- 资助金额:
$ 21.74万 - 项目类别:
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
人胰腺导管腺癌小鼠模型
- 批准号:
8451202 - 财政年份:2004
- 资助金额:
$ 21.74万 - 项目类别:
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
人胰腺导管腺癌小鼠模型
- 批准号:
8249079 - 财政年份:2004
- 资助金额:
$ 21.74万 - 项目类别:
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
人胰腺导管腺癌小鼠模型
- 批准号:
7436190 - 财政年份:2004
- 资助金额:
$ 21.74万 - 项目类别:
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
人胰腺导管腺癌小鼠模型
- 批准号:
6929917 - 财政年份:2004
- 资助金额:
$ 21.74万 - 项目类别:
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
人胰腺导管腺癌小鼠模型
- 批准号:
7114965 - 财政年份:2004
- 资助金额:
$ 21.74万 - 项目类别:
Mouse Model for Human Pancreatic Ductal Adenocarcinoma
人胰腺导管腺癌小鼠模型
- 批准号:
8625270 - 财政年份:2004
- 资助金额:
$ 21.74万 - 项目类别:
相似国自然基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
- 批准号:
23K08326 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
- 批准号:
23K14614 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
- 批准号:
23K15075 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
- 批准号:
23H02698 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
- 批准号:
10743611 - 财政年份:2023
- 资助金额:
$ 21.74万 - 项目类别: